Tech Company Financing Transactions
Aptimmune Biologics Funding Round
Aptimmune Biologics, operating out of St. Louis, secured $2.8 million from Arsenal Capital Partners and private investors.
Transaction Overview
Company Name
Announced On
7/10/2015
Transaction Type
Venture Equity
Amount
$2,750,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate its mucosal vaccine candidates through development and product registration.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1005 N. Warson Rd.
St. Louis, MS 63132
USA
St. Louis, MS 63132
USA
Phone
Website
Email Address
Not Recorded
Overview
Aptimmune Biologics specializes in developing revolutionary mucosal vaccines that provide unsurpassed efficacy against the viral diseases most costly to the swine industry. We focus solely on swine vaccines and the prevention of two major diseases -- Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and influenza.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Robert Nordgren
Chief Executive Officer
Heather Bessoff
Chief Scientific Officer
Federico Zuckermann
VP - Marketing
Andrew Smythe
Browse more venture capital transactions:
Prev: 7/10/2015: Polyverse venture capital transaction
Next: 7/10/2015: Simplus venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs